Insulet Corporation
- Branche
- Medical Devices
- Börse
- USA
- Land / Region
- USA
- Börsengang
- 15. Mai 2007
- Mitarbeiter
- 5.400
- Website
- www.insulet.com
Zusammengesetzter Bewertungsbereich · konservativ $110–$120 / fair $120–$160 / optimistisch $170–$190. Bei $165, Zwischen dem fairen und dem optimistischen Bereich.
Bei Veröffentlichung $144.94 (31. Mai 2026)
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Geschichte
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Branchenposition
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.